Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438515 | 1.00 | LIPG (0.47) | LIPGCTSKJAK2JAK1TYK2 | |
| SCHEMBL29518900 | 0.89 | LIPG (0.47) | LIPGCTSKJAK2JAK1TYK2 | |
| SCHEMBL21707305 | 0.89 | LIPG (0.47) | LIPGCTSKJAK2JAK1TYK2 | |
| SCHEMBL21733956 | 0.84 | LIPG (0.49) | LIPGCTSKJAK2JAK1TYK2 | |
| SCHEMBL30216265 | 0.84 | LIPG (0.49) | LIPGCTSKJAK2JAK1TYK2 | |
| SCHEMBL1909841 | 0.82 | LIPG (0.48) | LIPGCTSKJAK2JAK1TYK2 | |
| SCHEMBL29988255 | 0.82 | LIPG (0.47) | LIPGCTSKJAK2JAK1TYK2 | |
| SCHEMBL29988073 | 0.81 | LIPG (0.47) | LIPGCTSKJAK2JAK1TYK2 | |
| SCHEMBL443223 | 0.80 | KMT2A (0.43) | CTSKKMT2ATSHRHSD17B10ALDH1A1 | |
| SCHEMBL443224 | 0.80 | KMT2A (0.43) | CTSKKMT2ATSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | LIPG 289/4885CTSK 3044/4885JAK2 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.